Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers

Current Pharmaceutical Design

Volumn 14, Issue 25, 2008, Pages 2619-2634

  Stein, David A ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Antisense; Antiviral; Morpholino oligomer; PPMO; RNA virus

Indexed keywords

ANTIVIRUS AGENT; MESSENGER RNA; PEPTIDE CONJUGATED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG;

ALPHA VIRUS; ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ARTERIVIRUS; CORONAVIRUS; DENGUE VIRUS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EBOLA VIRUS; FLAVIVIRUS; HUMAN; INFLUENZA VIRUS; MEASLES VIRUS; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA SEQUENCE; RNA VIRUS; RNA VIRUS INFECTION; SPECIES DIFFERENCE; TOXICITY TESTING; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; MORPHOLINES; PEPTIDES; RNA VIRUS INFECTIONS; VIRUS REPLICATION;

EID: 57349187597     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786071290     Document Type: Review

References (100)

1. Schubert S, Kurreck J. Oligonucleotide-based antiviral strategies. Handb Exp Pharmacol 2006; (173): 261-87.
2. Lim TW, Yuan J, Liu Z, Qiu D, Sall A, Yang D. Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses. Curr Opin Mol Ther 2006; 8(2): 104-7.
3. Stein DA, Shi PY. Nucleic acid-based inhibition of flavivirus infections. Front Biosci 2008; 13: 1385-95.
4. Ulanova M, Schreiber AD, Befus AD. The future of antisense oligonucleotides in the treatment of respiratory diseases. BioDrugs 2006; 20(1): 1-11.
5. Lim T, Yuan J, Zhang HM, Sall A, Liu Z, Su Y, et al. Antisense DNA and RNA agents against picornaviruses. Front Biosci 2008; 13: 4707-25.
6. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008; 78(1): 26-36.
7. Trepanier JB, Tanner JE, Alfieri C. Oligonucleotide-based therapeutic options against hepatitis C virus infection. Antivir Ther 2006; 11(3): 273-87.
8. Peracchi A. Prospects for antiviral ribozymes and deoxyribozymes. Rev Med Virol 2004; 14(1): 47-64.
9. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11(1): 50-5.
10. Ketzinel-Gilad M, Shaul Y, Galun E. RNA interference for antiviral therapy. J Gene Med 2006; 8(8): 933-50.
11. Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol 2007; 25(12): 1435-43.
12. James W. Aptamers in the virologists' toolkit. J Gen Virol 2007; 88(Pt 2): 351-64.
13. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7(3): 187-95.
14. Stein D, Foster E, Huang SB, Weller D, Summerton J. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997; 7(3): 151-7.
15. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999; 1489(1): 141-58.
16. Heasman J. Morpholino oligos: making sense of antisense? Dev Biol 2002; 243(2): 209-14.
17. Nasevicius A, Ekker SC. Effective targeted gene 'knockdown' in zebrafish. Nat Genet 2000; 26(2): 216-20.
18. Karkare S, Bhatnagar D. Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol 2006; 71(5): 575-86.
19. Sumanas S, Larson JD. Morpholino phosphorodiamidate oligonucleotides in zebrafish: a recipe for functional genomics? Brief Funct Genomic Proteomic 2002; 1(3): 239-56.
20. Eisen JS, Smith JC. Controlling morpholino experiments: don't stop making antisense. Development 2008; 135(10): 1735-43.
21. Moulton JD, Yan YL. Using Morpholinos to control gene expression. Curr Protoc Mol Biol 2008; Chapter 26: Unit 26 8.
22. Ghosh C, Iversen PL. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev 2000; 10(4): 263-74.
23. Partridge M, Vincent A, Matthews P, Puma J, Stein D, Summerton J. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev 1996; 6(3): 169-75.
24. Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, Moulton HM, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005; 79(8): 4599-609.
25. Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2003 Feb; 13(1): 31-43.
26. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004; 15(2): 290-9.
27. Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, et al. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther 2000; 292(3): 921-8.
28. Nie G, Li Y, Wang M, Liu YX, Findlay JK, Salamonsen LA. Inhibiting uterine PC6 blocks embryo implantation: an obligatory role for a proprotein convertase in fertility. Biol Reprod 2005; 72(4): 1029-36.
29. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003; 9(7): 2510-9.
30. Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer 2008; 60(3): 347-54.
31. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003; 10(11): 823-32.
32. Arora V, Cate ML, Ghosh C, Iversen PL. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos 2002; 30(7): 757-62.
33. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, et al. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 2004; 172(3): 1140-4.
34. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12(2): 175-7.
35. Vitiello L, Bassi N, Campagnolo P, Zaccariotto E, Occhi G, Malerba A, et al. In vivo delivery of naked antisense oligos in aged mdx mice: Analysis of dystrophin restoration in skeletal and cardiac muscle. Neuromuscul Disord 2008; 18(8): 597-605.
36. Mae M, Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 2006; 6(5): 509-14.
37. Wagstaff KM, Jans DA. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem 2006; 13(12): 1371-87.
38. Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL, et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 2007; 35(15): 5182-91.
39. Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)(4) peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116(3): 304-13.
40. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008; 60(4-5): 517-29.
41. Lai SH, Stein DA, Guerrero-Plata A, Liao SL, Ivanciuc T, Hong C, et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther 2008; 16(6): 1120-8.
42. Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug Chem 2005; 16(4): 959-66.
43. Flint SJ, Enquist LW, Rancaniello VR, Skalka AM. Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses 2nd ed. Washington D.C.: ASM Press; 2003.
44. Knipe DM, Howley PM. Fields Virology. Fifth ed. Knipe DM, Howley PM, Eds. Philidelphia, PA: Lippincott, Williams, and Wilkins; 2007.
45. Stein DA, Skilling DE, Iversen PL, Smith AW. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2001; 11(5): 317-25.
46. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, et al. Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers. PLoS Pathog 2006; 2(1): e1.
47. Smith AW, Iversen PL, O'Hanley PD, Skilling DE, Christensen JR, Weaver SS, et al. Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. Am J Vet Res 2008; 69(1): 23-32.
48. Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, et al. VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice. Antimicrob Agents Chemother 2006; 50(3): 984-93.
49. Warfield KL, Panchal RG, Aman MJ, Bavari S. Antisense treatments for biothreat agents. Curr Opin Mol Ther 2006; 8(2): 93-103.
50. Iversen PL. Morpholinos. In: Crooke ST, Ed. Antisense Drug Technology. Second ed. Boca Raton, FL: CRC Press 2008; 565-82.
51. Deas TS, Bennett CJ, Jones SA, Tilgner M, Ren P, Behr MJ, et al. In vitro Resistance Selection and In Vivo Efficacy of Morpholino Oligomers against West Nile Virus. Antimicrob Agents Chemother 2007; 51(7): 2470-82.
52. Burrer R, Neuman BW, Ting JP, Stein DA, Moulton HM, Iversen PL, et al. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J Virol 2007; 81(11): 5637-48.
53. Lupfer C, Stein DA, Mourich DV, Tepper SE, Iversen PL, Pastey M. Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Arch Virol 2008; 153(5): 929-37.
54. Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, Blouch RE, et al. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother 2008; 62(3): 555-65.
55. Salonen A, Ahola T, Kaariainen L. Viral RNA replication in association with cellular membranes. Curr Top Microbiol Immunol 2005; 285: 139-73.
56. Novoa RR, Calderita G, Arranz R, Fontana J, Granzow H, Risco C. Virus factories: associations of cell organelles for viral replication and morphogenesis. Biol Cell 2005; 97(2): 147-72.
57. Miller S, Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol 2008; 6(5): 363-74.
58. Holden KL, Stein DA, Pierson TC, Ahmed AA, Clyde K, Iversen PL, et al. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. Virology 2006; 344(2): 439-52.
59. Kinney RM, Huang CY, Rose BC, Kroeker AD, Dreher TW, Iversen PL, et al. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J Virol 2005; 79(8): 5116-28.
60. Zhang B, Dong H, Stein DA, Iversen PL, Shi PY. West Nile virus genome cyclization and RNA replication require two pairs of longdistance RNA interactions. Virology 2008; 373(1): 1-13.
61. Dong H, Ray D, Ren S, Zhang B, Puig-Basagoiti F, Takagi Y, et al. Distinct RNA elements confer specificity to flavivirus RNA cap methylation events. J Virol 2007; 81(9): 4412-21.
62. Lindenbach BD, Theil HJ, Rice CM. Flaviviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, Eds. Fields Virology. Fifth ed. Philidelphia, PA: Lippincott, Williams, and Wilkins 2007; Chapter 33.
63. Khromykh AA, Meka H, Guyatt KJ, Westaway EG. Essential role of cyclization sequences in flavivirus RNA replication. J Virol 2001; 75(14): 6719-28.
64. Alvarez DE, Lodeiro MF, Luduena SJ, Pietrasanta LI, Gamarnik AV. Long-range RNA-RNA interactions circularize the dengue virus genome. J Virol 2005; 79(11): 6631-43.
65. Neuman BW, Stein DA, Kroeker AD, Churchill MJ, Kim AM, Kuhn P, et al. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J Virol 2005; 79(15): 9665-76.
66. Neuman BW, Stein DA, Kroeker AD, Paulino AD, Moulton HM, Iversen PL, et al. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J Virol 2004; 78(11): 5891-9.
67. van den Born E, Stein DA, Iversen PL, Snijder EJ. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J Gen Virol 2005; 86(Pt 11): 3081-90.
68. Zhang YJ, Stein DA, Fan SM, Wang KY, Kroeker AD, Meng XJ, et al. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Vet Microbiol 2006; 117(2-4): 117-29.
69. Patel D, Opriessnig T, Stein DA, Halbur PG, Meng XJ, Iversen PL, et al. Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antiviral Res 2008; 77(2): 95-107.
70. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol 2007; 81(1): 20-9.
71. Snijder EJ, Spaan WJM. Arteriviruses. In: Knipe DM, Howley PM, Eds. Fields Virology. Fifth ed. Philadelphia, PA: Lippincott, Williams, and Wilkins 2007; 1337-55.
72. Lai MCM, Perlman S, Anderson LJ. Coronaviridae. In: Knipe DM, Howley PM, Eds. Fields virology. Fifth ed. Philadelphia, PA: Lippincott, Williams, and Wilkins 2007; 1305-35.
73. van Den Born E, Gultyaev AP, Snijder EJ. Secondary structure and function of the 5′-proximal region of the equine arteritis virus RNA genome. RNA 2004; 10(3): 424-37.
74. Kang H, Feng M, Schroeder ME, Giedroc DP, Leibowitz JL. Putative cis-acting stem-loops in the 5′ untranslated region of the severe acute respiratory syndrome coronavirus can substitute for their mouse hepatitis virus counterparts. J Virol 2006; 80(21): 10600-14.
75. Yuan J, Stein DA, Lim T, Qiu D, Coughlin S, Liu Z, et al. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptideconjugated morpholino oligomers targeting the internal ribosome entry site. J Virol 2006; 80(23): 11510-9.
76. Paessler S, Rijnbrand R, Stein DA, Ni H, Yun NE, Dziuba N, et al. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 2008; 376(2): 357-70.
77. Ehrenfeld E, Teterina NL. Initiation of Translation of Picornavirus RNAs: Structure and Function of the Internal Ribosome Entry Site. In: Wimmer E, Semler BL, Eds. Molecular Biology of Picornaviruses. Washington DC: American Socirty for Microbiology 2002; 159-69.
78. Racaniello VR. Picornaviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, Eds. Fields Virology. Fifth ed. Philadelphia, PA: Lippincott, Williams, and Wilkins 2007; 795-838.
79. Stone JK, Rijnbrand R, Stein DA, Ma Y, Yang Y, Iversen PL, et al. A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus. Antimicrob Agents Chemother 2008; 52(6): 1970-81.
80. Martinez-Salas E. The impact of RNA structure on picornavirus IRES activity. Trends Microbiol 2008; 16(5): 230-7.
81. Vagnozzi A, Stein DA, Iversen PL, Rieder E. Inhibition of foot-and- mouth disease virus infections in cell cultures with antisense morpholino oligomers. J Virol 2007; 81(21): 11669-80.
82. Le Mercier P, Garcin D, Hausmann S, Kolakofsky D. Ambisense sendai viruses are inherently unstable but are useful to study viral RNA synthesis. J Virol 2002; 76(11): 5492-502.
83. Cowton VM, McGivern DR, Fearns R. Unravelling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol 2006; 87(Pt 7): 1805-21.
84. Ge Q, Pastey M, Kobasa D, Puthavathana P, Lupfer C, Bestwick RK, et al. Inhibition of multiple subtypes of influenza a virus in cell cultures with morpholino oligomers. Antimicrob Agents Chemother 2006; 50(11): 3724-33.
85. Gabriel G, Nordmann A, Stein DA, Iversen PL, Klenk HD. Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. J Gen Virol 2008; 89(Pt 4): 939-48.
86. You S, Padmanabhan R. A novel in vitro replication system for Dengue virus. Initiation of RNA synthesis at the 3′-end of exogenous viral RNA templates requires 5′- and 3′-terminal complementary sequence motifs of the viral RNA. J Biol Chem 1999; 274(47): 33714-22.
87. van Hemert MJ, de Wilde AH, Gorbalenya AE, Snijder EJ. The in vitro RNA synthesizing activity of the isolated arterivirus replication/transcription complex is dependent on a host factor. J Biol Chem 2008; 283(24): 16525-36.
88. Nomaguchi M, Teramoto T, Yu L, Markoff L, Padmanabhan R. Requirements for West Nile virus (-)- and (+)-strand subgenomic RNA synthesis in vitro by the viral RNA-dependent RNA polymerase expressed in Escherichia coli. J Biol Chem 2004; 279(13): 12141-51.
89. Thurner C, Witwer C, Hofacker IL, Stadler PF. Conserved RNA secondary structures in Flaviviridae genomes. J Gen Virol 2004; 85(Pt 5): 1113-24.
90. Malnou CE, Poyry TA, Jackson RJ, Kean KM. Poliovirus internal ribosome entry segment structure alterations that specifically affect function in neuronal cells: molecular genetic analysis. J Virol 2002; 76(21): 10617-26.
91. Neumann G, Brownlee GG, Fodor E, Kawaoka Y. Orthomyxovirus replication, transcription, and polyadenylation. Curr Top Microbiol Immunol 2004; 283: 121-43.
92. Weik M, Enterlein S, Schlenz K, Muhlberger E. The Ebola virus genomic replication promoter is bipartite and follows the rule of six. J Virol 2005; 79(16): 10660-71.
93. Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 2007; 18(4): 1325-31.
94. Arora V, Devi GR, Iversen PL. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 2004; 5(5): 431-9.
95. Liu G, He J, Zhang S, Liu C, Rusckowski M, Hnatowich DJ. Cytosine residues influence kidney accumulations of 99mTc-labeled morpholino oligomers. Antisense Nucleic Acid Drug Dev 2002; 12(6): 393-8.
96. Liu G, Zhang S, He J, Liu N, Gupta S, Rusckowski M, et al. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice. Q J Nucl Med 2002; 46(3): 233-43.
97. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, et al. Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice. Mol Ther 2008; 16(9): 1624-29.
98. Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM. Stability of cell-penetrating Peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 2007; 18(1): 50-60.
99. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, et al. Morpholino Oligomer-Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse. Mol Ther 2007; 15(9): 1587-92.
100. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006; 13(19): 1373-81.